Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:38:05 EDT Sat 21 Jun 2025
Enter Symbol
or Name
USA
CA



Q:ENGN - ENGENE HOLDINGS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ENGN - Q0.12.75·3.610.13.15-0.14-4.379.12236273.30  3.345  2.995911.00  2.6618:11:21Jun 1715 min RT 2¢

Recent Trades - Last 10 of 627
Time ETExPriceChangeVolume
18:11:21Q3.31950.02951
18:08:48Q3.00-0.292
17:53:13Q3.300.012
17:44:10Q3.00-0.293
16:00:14Q3.15-0.141
16:00:01Q3.15-0.14923
16:00:01Q3.15-0.1430
16:00:01Q3.15-0.14300
16:00:01Q3.15-0.14200
15:59:59Q3.125-0.165150

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-17 08:00U:ENGNNews ReleaseenGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-06-12 08:00U:ENGNNews ReleaseenGene Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-06-04 08:30U:ENGNNews ReleaseenGene Announces the Resignation of its Chief Medical Officer
2025-05-29 08:00U:ENGNNews ReleaseenGene to Present at the Jefferies Global Healthcare Conference
2025-05-28 07:30U:ENGNNews ReleaseenGene Names Amy Pott as Chief Global Commercialization Officer
2025-04-28 08:00U:ENGNNews ReleaseenGene to Participate in Upcoming Investor Conferences
2025-04-04 08:00U:ENGNNews ReleaseenGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-04-01 08:00U:ENGNNews ReleaseenGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
2025-03-10 16:05U:ENGNNews ReleaseenGene Reports First Quarter 2025 Financial Results and Provides Business Update
2025-03-04 08:00U:ENGNNews ReleaseenGene to Participate in the Leerink Partners Global Healthcare Conference
2025-02-04 08:00U:ENGNNews ReleaseenGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
2025-01-31 16:05U:ENGNNews ReleaseenGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2025-01-30 08:00U:ENGNNews ReleaseenGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
2024-12-30 16:05U:ENGNNews ReleaseenGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-12-19 16:05U:ENGNNews ReleaseenGene Reports Full Year 2024 Financial Results and Provides a Business Update
2024-11-25 08:00U:ENGNNews ReleaseenGene to Participate in Upcoming Investor Conferences
2024-11-05 08:00U:ENGNNews ReleaseenGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
2024-10-25 08:00U:ENGNNews ReleaseenGene Announces $60 Million Private Placement Financing
2024-10-22 16:05U:ENGNNews ReleaseenGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
2024-10-21 08:45U:ENGNNews ReleaseenGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer